Shire ADHD alliance gives more power to Shionogi's diversifying lineup
This article was originally published in Scrip
Shionogi is to co-develop and co-commercialise in Japan two drugs for attention-deficit hyperactivity disorder (ADHD) licensed from Shire, in a deal that adds to the Japanese firm's steady move away from its lacklustre anti-infectives business.
You may also be interested in...
While it has raised the full-year profit outlook, Takeda came in under analysts' consensus for some of its fiscal first-half figures, pointing to a growing forex impact.
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.